NCT03259867View on ClinicalTrials.gov

Combination of TATE and PD-1 Inhibitor in Liver Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

July 1, 2017

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Hepatocellular CarcinomaGastric Cancer
Interventions
DRUG

Nivolumab Injectable Product

a PD-1 immune check inhibitor

COMBINATION_PRODUCT

Trans-arterial tirapazamine embolization

Embolization with Lipiodol and Gelfoam

Trial Locations (3)

53226

RECRUITING

Medical College of Wisconsin, Milwaukee

73104

RECRUITING

University of Oklahoma Health Science Center, Oklahoma City

92868

RECRUITING

University of California, Irvine, Orange

All Listed Sponsors
lead

Teclison Ltd.

INDUSTRY

NCT03259867 - Combination of TATE and PD-1 Inhibitor in Liver Cancer | Biotech Hunter | Biotech Hunter